Nipro Corporation (Japanese: ニプロ株式会社, Nipuro Kabushiki-gaisha) is a Japanese multinational healthcare company headquartered in Settsu, Osaka, Japan. Founded in 1954, Nipro has developed from a company involved in glass materials and medical supplies into a diversified global healthcare manufacturer whose activities span medical devices, pharmaceuticals, pharmaceutical packaging, and regenerative medicine.

The latest company profile lists 38,593 consolidated employees and confirms Nipro’s listing on the Prime Market of the Tokyo Stock Exchange.1

1954–1960s: Origins in glass and medical supplies

Nipro was established on July 8, 1954, originally operating under the name Nippon Glass Shoji Co., Ltd. The company’s early business centered on glass products and instruments, including glass tubes used for ampoules and pharmaceutical containers.

The company’s experience with glass technology eventually provided a foundation for entering healthcare manufacturing.

In 1965, Nipro entered the medical-equipment business. It began developing and selling medical products under the NIPRO brand, including dialysis-related products and infusion lines. Dialyzers subsequently became one of the company’s most important product categories.

1970s–1990s: Expansion into medical technology

Nipro expanded its medical-device portfolio beyond dialysis into areas such as infusion therapy, injection products and other disposable medical products.

Its development of dialysis equipment and dialyzers became particularly important to its international healthcare business. The company gradually established manufacturing and sales operations outside Japan.

2000s: Nipro becomes the corporate identity

A significant milestone came in 2001, when the company absorbed a domestic sales subsidiary and adopted the name Nipro Corporation, using the internationally recognized NIPRO brand as its corporate name. It also reorganized its businesses around medical and pharmaceutical activities.

During this period, Nipro increasingly positioned itself as an integrated healthcare company rather than simply a medical-device manufacturer.

2010s–present: Global healthcare group

Nipro subsequently expanded its international operations and strengthened its pharmaceutical and pharmaceutical-packaging businesses.

Today, the company describes its business around four principal areas:

1. Medical Devices
2. Pharmaceuticals
3. PharmaPackaging
4. Regenerative Medicine

Nipro’s current strategy emphasizes becoming a global comprehensive healthcare company, combining manufacturing, technology, research, pharmaceuticals and medical solutions.

1. Medical Devices

Medical devices remain one of Nipro’s core businesses. The company’s portfolio includes products for:

• Dialysis and renal care
• Injection and infusion
• Catheter-based and interventional procedures
• Hospital care
• Cardiopulmonary applications
• Artificial organs
• Diabetes management
• Medical disposables
• Blood collection and related applications

Nipro specifically describes its medical-device business as covering dialysis products, catheters, hospital disposables, cardiopulmonary products and other specialized healthcare products.

Dialysis

Dialysis is particularly important to Nipro’s history and identity. Nipro manufactures products used throughout the hemodialysis process, including dialyzers, dialysis machines and related consumables. Its current renal-care offering is positioned as a comprehensive solution extending from water-treatment systems and dialysis equipment to disposables and concentrates.

A dialyzer is sometimes informally described as an “artificial kidney.” It performs the blood-filtration function required during hemodialysis by removing waste products and excess fluid from a patient’s blood.

2. Pharmaceuticals

Nipro is also active in pharmaceutical manufacturing. Its pharmaceutical business includes contract development and manufacturing, commonly known as CDMO. In this role, Nipro can manufacture pharmaceutical products on behalf of other pharmaceutical companies rather than only selling medicines under the Nipro name.

Its activities include areas such as:

• Injectable medicines
• Oral medicines
• External preparations
• Pharmaceutical combination products
• Pharmaceutical manufacturing services

This gives Nipro a position across multiple stages of the healthcare supply chain—from pharmaceutical packaging and drug manufacturing to medical-device delivery systems.2

3. PharmaPackaging

Pharmaceutical packaging is one of Nipro’s oldest areas of expertise because the company originated in the glass industry. The business produces packaging and components used by pharmaceutical manufacturers, including:

• Pharmaceutical glass tubing
• Glass containers
• Vials
• Ampoules
• Rubber stoppers
• Drug-administration systems
• Other pharmaceutical packaging components

Nipro describes this business as providing comprehensive pharmaceutical-packaging solutions, from glass tubing through finished products.3

This is strategically important because pharmaceutical packaging must protect medicines from contamination, maintain product stability and support safe administration.

4. Regenerative Medicine

Nipro has also expanded into regenerative medicine, which the company identifies as a newer business pillar. This area involves technologies associated with tissue engineering, cell processing and regenerative therapies.

Nipro operates dedicated research and development facilities, including a Research & Development Center for Regenerative Medicine in Sapporo and cell-processing facilities in Japan.

The company’s expansion into regenerative medicine represents a move beyond conventional medical devices toward emerging healthcare technologies.

Research and technological development are central to Nipro’s strategy. The company operates multiple R&D facilities in Japan, including:

• NIPRO Creative Innovation Center
• Pharmaceutical Research Center
• Research & Development Center for Regenerative Medicine
• Production Technology Center

Nipro says it develops products at four R&D sites while combining technologies developed across its different businesses.4

This gives the company an unusual combination of expertise in materials science, medical devices, pharmaceuticals and manufacturing technology.

Although Nipro is a Japanese company, its operations are international. The Nipro Group has established production, sales and research operations across multiple regions, serving hospitals, healthcare professionals, pharmaceutical companies and patients.

The company’s international business covers areas including:

• Asia
• Europe
• North America
• Latin America
• Other international markets

Nipro’s international expansion has been particularly significant in dialysis, medical devices and pharmaceutical packaging.

The company also operates through regional subsidiaries. For example, Nipro Asia manages sales, marketing and business operations for the Asia-Pacific region.

Interestingly, Nipro announced in September 2026 that it established an Asia Pacific Regional Headquarters in Singapore, intended to unify regional operations under its “One NIPRO” approach.

The NIPRO name is used across the group’s international healthcare businesses. The company’s corporate logo incorporates the letter N together with an infinity symbol, representing the company’s aspiration for sustained growth and continued value creation with society.

Nipro’s current consumer-facing slogan is:

“Live longer. Live better.”

The company positions this around improving patients’ quality of life and supporting healthcare professionals.

Its corporate philosophy also emphasizes “Willingness”, referring to employees’ willingness to consider healthcare needs and contribute to society.5

At the top of the group is Nipro Corporation, headquartered in Osaka. The company operates through a large network of subsidiaries and affiliated companies around the world. These entities specialize in areas such as:

• Medical-device manufacturing
• Dialysis
• Pharmaceuticals
• Pharmaceutical packaging
• Sales and distribution
• Research and development
• Regional healthcare operations

As of March 31, 2026, Nipro Corporation itself reported 4,714 employees, while the consolidated Nipro Group had 38,593 employees.

As of 2026, the company’s leadership includes:

• Yoshihiko Sano — Chairperson and Representative Director
• Tsuyoshi Yamazaki — Representative Board Director, President and CEO

The current leadership describes Nipro’s long-term objective as becoming a truly global, comprehensive healthcare company while maintaining its Japanese corporate philosophy of WA-gokoro, or harmony.

Nipro Corporation is a publicly traded Japanese company. Its shares are listed on the Tokyo Stock Exchange — Prime Market. The company’s stock code is 8086. Its corporate capital was approximately ¥84.4 billion as of March 31, 2026.

One way to understand Nipro is to look at where it sits in the healthcare ecosystem. A pharmaceutical company might primarily discover and sell medicines. A medical-device company might primarily manufacture equipment used by hospitals. Nipro does both—and also supplies some of the infrastructure surrounding those products.

For example:

Pharmaceutical company → Nipro pharmaceutical packaging → medicine → Nipro injection/infusion device → patient

Or:

Hospital → Nipro dialysis machine + dialyzer + dialysis consumables → dialysis treatment → patient

This vertically connected approach is one of Nipro’s distinctive characteristics.

Nipro’s major distinguishing feature is the combination of several healthcare businesses under one group. Its main strengths are:

• Long history — established in 1954.
• Dialysis expertise — one of the company’s historically important fields.
• Medical-device manufacturing — extensive portfolio across hospitals and specialized medicine.
• Pharmaceutical manufacturing — including CDMO activities.
• Pharmaceutical packaging — an area connected directly to its original glass expertise.
• Regenerative medicine — newer technology area.
• Vertical integration — capabilities spanning materials, packaging, medicines, devices and healthcare.
• Global operations — international manufacturing, sales and R&D network.
• Japanese manufacturing heritage — strong emphasis on quality, reliability and technological development.

Nipro itself describes its major strength as the combination—or “trinity”—of medical devices, pharmaceuticals and pharma packaging, with regenerative medicine becoming an additional business pillar.

1. Nipro Corporation
2. Medical Device Business | Our Business | NIPRO CORPORATION
3. Our expertises | Nipro
4. Homepage | Nipro
5. About Us – Nipro Asia | Live Longer Live Better | Nipro Asia